Hepion Pharmaceuticals, Inc. 8-KCurrent Reports (8-K / ad hoc)

Changes / Accountants

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 4.1 Form of Convertible Note 4.2 Form of Warrant 10.1 Form of Convertible Note Purchase Agreement. 10.2 Form of Convertible Note Security Agreement 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Field: Page; Sequence: 2; Options: NewSection; Value: 2 - Field: Sequence; Type: Arabic; Name: PageNo 2 Field: /Sequence - Field: /Page SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 8, 2026 Hepion Pharmaceuticals, Inc. By: /s/ Gary Stetz Gary Stetz Interim Chief Executive Officer Field: Page; Sequence: 3; Options: Last - Field: Sequence; Type: Arabic; Name: PageNo 3 Field: /Sequence - Field: /Page Field: Set; Name: xdx; ID: xdx_08B_extensions eJxFjd0KwjAMhZ9g7xB6PWY3VHSXjjnEKTJEvC0uSnFrRlr/Hsm3tG6IIRCSc74cIUJR0FI3yHBcVCXsse0a5RAqPCOjOaF3ZKt1Cn5WeNHWsTKuX39gRp5Bz0yjycnfe+ddW6xTkPORnI2SKcg4jcew24jgq2dkzrpG47RqQJkadkwda3SKX8OHvXqSofbVJx2QrSaTQhzJQX5DIuMEtnRXD+KrhbLMRBD2FYiC6dZ5V/50aL4k5A22Ps4O9L+DD9FxSmU=